This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Staar Surgical (STAA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Staar Surgical (STAA) closed the most recent trading day at $77.97, moving -1.73% from the previous trading session.
STAAR Surgical (STAA) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Strong growth in EVO ICL units led by increased market adoption is likely to have driven STAAR Surgical's (STAA) Q4 revenues.
STAAR Surgical Company (STAA) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Staar Surgical (STAA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Cardinal Health (CAH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 16.81% and 2.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
AmerisourceBergen (ABC) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
AmerisourceBergen (ABC) delivered earnings and revenue surprises of 3.44% and 0.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical (STAA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Staar Surgical (STAA) closed the most recent trading day at $69.42, moving +0.78% from the previous trading session.
Staar Surgical (STAA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Staar Surgical (STAA) closed at $73.93, marking a +1.97% move from the previous day.
Why You Should Hold Elevance Health (ELV) in Your Portfolio
by Zacks Equity Research
Elevance Health (ELV) remains well-poised for growth due to a growing customer base within its Government and IngenioRx businesses coupled with solid cash-generating abilities.
Teladoc (TDOC) Unveils App to Simplify Whole-Person Care
by Zacks Equity Research
Teladoc Health (TDOC) launches a digital app that will provide a broad range of TDOC's services to cater to the whole-person health needs of members.
Here's Why You Should Hold Cigna (CI) Stock in Your Portfolio
by Zacks Equity Research
Cigna (CI) remains well-poised for growth on the back of the solid Evernorth and Cigna Healthcare businesses, an expanding customer base and robust cash-generating abilities.
Community Health (CYH) Sells Hospital, Renews Health Net Tie-Up
by Zacks Equity Research
Community Health (CYH) announces the divestiture of its West Virginia hospital and the expansion of its alliance with Health Net, thereby undertaking initiatives to boost business prospects.
New Strong Buy Stocks for January 4th
by Zacks Equity Research
STAA, CASY, THRM, MP and UTHR have been added to the Zacks Rank #1 (Strong Buy) List on January 4 , 2023.
Is the Options Market Predicting a Spike in STAAR Surgical (STAA) Stock?
by Zacks Equity Research
Investors need to pay close attention to STAAR Surgical (STAA) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in STAAR (STAA) Stock?
by Zacks Equity Research
Investors need to pay close attention to STAAR (STAA) stock based on the movements in the options market lately.
Staar Surgical (STAA) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 76.19% and 1.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
LabCorp (LH) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
LabCorp (LH) delivered earnings and revenue surprises of -0.64% and 5.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
3 Reasons Why Growth Investors Shouldn't Overlook Staar Surgical (STAA)
by Zacks Equity Research
Staar Surgical (STAA) possesses solid growth attributes, which could help it handily outperform the market.
Is Staar Surgical (STAA) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Staar Surgical (STAA) could produce exceptional returns because of its solid growth attributes.
Staar Surgical (STAA) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Staar Surgical (STAA) could produce exceptional returns because of its solid growth attributes.
3 Reasons Growth Investors Will Love Staar Surgical (STAA)
by Zacks Equity Research
Staar Surgical (STAA) possesses solid growth attributes, which could help it handily outperform the market.
What Makes Staar Surgical (STAA) a New Buy Stock
by Zacks Equity Research
Staar Surgical (STAA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Glaukos (GKOS) Strong Portfolio Driving Sales Amid Competition
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.
Staar Surgical (STAA) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 68% and 1.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SmileDirectClub (SDC) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
SmileDirectClub (SDC) delivered earnings and revenue surprises of -21.43% and 13.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Henry Schein (HSIC) Beats Q2 Earnings Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 3.57% and 2.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?